

**OCUMETICS TECHNOLOGY CORP.**

**P R E S S   R E L E A S E**

**Ocumetics Announces Corporate Changes**

***For Immediate Release***

**Calgary, Alberta** – May 1, 2025. Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) (the “**Corporation**” or “**Ocumetics**”) announces that Mr. Dayton Marks has resigned as a director of the Corporation.

“On behalf of the Ocumetics board of directors, I would like to thank Dayton for his contributions to Ocumetics,” said Dr. Garth Webb, Ocumetics’ Founder and Chairman of the Board. “We are thankful for his significant efforts and contributions to the Corporation. We wish him well in his future endeavours.”

**About Ocumetics**

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

**FOR FURTHER INFORMATION, PLEASE CONTACT:**

Dean Burns  
President and CEO  
(817) 874-7564

Roger Jewett  
Chief Financial Officer  
roger.jewett@ocumetics.com

***Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.***